NIMOTOP Drug Patent Profile

When do Nimotop patents expire, and what generic alternatives are available?

Nimotop is a drug marketed by Bayer Pharms and is included in one NDA.

The generic ingredient in NIMOTOP is nimodipine. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nimodipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nimotop

A generic version of NIMOTOP was approved as nimodipine by HERITAGE on May 2^nd, 2007.

Summary for NIMOTOP

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	9
Patent Applications:	4,622
DailyMed Link:	NIMOTOP at DailyMed

Recent Clinical Trials for NIMOTOP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Health Network, Toronto	Early Phase 1
Medical University of Vienna	Phase 2
Amsterdam University Medical Center	Phase 2

See all NIMOTOP clinical trials

US Patents and Regulatory Information for NIMOTOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	NIMOTOP	nimodipine	CAPSULE;ORAL	018869-001	Dec 28, 1988		DISCN	Yes	No

Expired US Patents for NIMOTOP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Pharms	NIMOTOP	nimodipine	CAPSULE;ORAL	018869-001	Dec 28, 1988	3,799,934
Bayer Pharms	NIMOTOP	nimodipine	CAPSULE;ORAL	018869-001	Dec 28, 1988	3,932,645
Bayer Pharms	NIMOTOP	nimodipine	CAPSULE;ORAL	018869-001	Dec 28, 1988	4,406,906

International Patents for NIMOTOP

See the table below for patents covering NIMOTOP around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S54135776	PHARMACEUTICAL COMPOSITION AND METHOD
Switzerland	571492
Romania	62643
Poland	92407
Sweden	371823

NIMOTOP Market Analysis and Financial Projection

Last updated: February 17, 2026

What Are the Market Dynamics of NIMOTOP?

NIMOTOP (nimotuzumab) is a monoclonal antibody developed by Biocon and Huadong Medicine, approved in some regions for the treatment of certain cancers, notably gliomas and head and neck squamous cell carcinomas. Its market penetration remains limited primarily due to competition from established therapies and challenges in regulatory approval across key markets.

Market Size and Competitive Landscape

The global oncology monoclonal antibody market was valued at approximately $120 billion in 2022, with key players including Roche, Pfizer, and Merck. NIMOTOP’s primary competitors are other EGFR-targeting therapies such as cetuximab and necitumumab.

The specific segment involving nimotuzumab is smaller, with estimated sales in the low hundreds of millions USD annually, predominantly in China and select Asian markets. Its market share remains under 5%, hindered by limited approved indications and lesser availability outside China.

Regulatory Environment

NIMOTOP's approval status varies:

• China: Approved for nasopharyngeal carcinoma, head and neck cancers, gliomas.
• India: Approved as an adjuvant therapy.
• Global: Limited or no approval in the US and Europe, restricting market access.

Regulatory approvals are contingent on ongoing clinical trials demonstrating efficacy and safety profiles competitive with existing therapies.

Prescribing Trends and Adoption Drivers

Physician adoption hinges on clinical trial outcomes, reimbursement policies, and comparative effectiveness. Factors influencing growth include:

• Evidence of improved survival or quality of life.
• Cost-effectiveness relative to competitors.
• Expansion of indications supported by trial data.

Despite these drivers, uptake has been slow outside China due to regulatory hurdles and market preferences for proven biologics with broad international approvals.

Pricing and Reimbursement Environment

Pricing strategies for NIMOTOP are region-specific. In China, prices range from $1,000 to $2,500 per treatment course. Reimbursement policies for oncology biologics favor established drugs with extensive clinical data, posing challenges for newer entrants like NIMOTOP.

Variable reimbursement policies across health systems influence sales volume, with government coverage being a significant determinant in Asian markets.

What Is the Financial Trajectory for NIMOTOP?

Revenue Projections

NIMOTOP’s revenues have shown modest growth, with sales figures:

Year	Estimated Revenue (USD millions)	Notes
2020	120	Primarily in China
2021	150	Slight growth, new approvals in India
2022	180	regional expansion, licensing agreements

Future revenue depends heavily on:

• Expanding indications through clinical trials.
• Approval for new markets, notably US and Europe.
• Strategic licensing or partnership deals.

Profitability Outlook

Cost of goods sold (COGS) for monoclonal antibodies typically ranges from 20-30%, depending on scale and manufacturing efficiency. Profit margins are often narrow due to pricing pressures.

Operational costs include R&D, clinical trials, regulatory compliance, and marketing. Given current market penetration, NIMOTOP operates at a loss or marginal profit, with potential to turn profitable as sales volume increases and margins improve with scale.

Investment and R&D Considerations

Biocon and Huadong have invested in R&D and clinical trials to expand uses, with a focus on head and neck cancers and gliomas. Cost estimates for ongoing trials:

• Phase III trials: $50-100 million per indication.
• Regulatory submission and approval: $20-50 million per region.

Potential partnerships with larger pharma companies could reduce internal R&D costs and accelerate market entry for additional indications.

Market Entry and Expansion Strategies

Expanding into US or European markets requires substantial investment in trials and regulatory compliance, with approval timelines stretching 3-7 years. Alternatively, partnership agreements could facilitate faster access, reduce capital expenditure, and leverage existing distribution channels.

Risks and Challenges

Major risks include:

• Competition from more established biologics.
• Regulatory delays or rejections.
• Pricing pressures leading to reduced margins.
• Limited global presence compared to competitors.

Key Takeaways

• NIMOTOP remains a niche product with constrained market presence outside select Asian countries.
• Revenue growth is driven by regional expansion, new indications, and licensing deals.
• The financial trajectory depends on successful clinical trials, regulatory approvals, and competitive positioning.
• Profitability will improve with increased sales volume, scaled manufacturing, and potentially through strategic partnerships.
• Market competition and reimbursement policies are primary risks impacting long-term financial success.

FAQs

1. How does NIMOTOP compare to other EGFR inhibitors?
NIMOTOP has a distinct profile with fewer side effects and cost advantages in some markets but lacks widespread approval, limiting its competitive reach compared to globally marketed EGFR inhibitors like cetuximab.

2. What are the key barriers to NIMOTOP's expansion into Western markets?
Regulatory approval requirements, lack of sufficient clinical data in diverse populations, and established competition are primary barriers.

3. Are there ongoing clinical trials for NIMOTOP?
Yes, trials focused on different cancer indications are ongoing in China and elsewhere, aiming to expand its approved uses.

4. What is the outlook for NIMOTOP’s profitability?
Long-term profitability hinges on approval for additional indications, broader market access, and economies of scale, which could reduce manufacturing costs.

5. How does pricing affect NIMOTOP’s market penetration?
Competitive pricing in Asian markets has facilitated adoption, but high prices in developed markets without approval could hinder growth.

---

Sources:

1. MarketWatch. “Global Oncology Monoclonal Antibody Market Analysis.” 2022.
2. Biocon Ltd. “NIMOTOP Clinical Data & Approvals.” 2022.
3. IQVIA. “Global Oncology Biologics Market Data.” 2022.
4. Chinese National Medical Products Administration (NMPA). “NIMOTOP Approvals and Indications.” 2023.
5. EvaluatePharma. “Biologics Market Forecast.” 2022.